# Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

> **NCT00790647** · PHASE2 · COMPLETED · sponsor: **Boston Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** bortezomib
- **DRUG:** melphalan
- **PROCEDURE:** Stem Cell Infusion

## Key facts

- **NCT ID:** NCT00790647
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-12
- **Final completion:** 2014-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790647, "Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00790647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*